Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer
Roche’s pharma chief Bill Anderson is taking a victory lap before he steps down at the end of the year.
The FDA last week approved …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
